Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Jun;34(6):1041–1044. doi: 10.1128/aac.34.6.1041

Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.

A Verghese 1, D Roberson 1, J H Kalbfleisch 1, F Sarubbi 1
PMCID: PMC171754  PMID: 2118322

Abstract

Patients with purulent exacerbation of chronic bronchitis were randomized to receive either a single 400-mg daily dose of cefixime or 250 mg of cephalexin, orally, four times a day. Patients were males with a mean age of 63 years. Of the 86 patients, 71 (82%) had bronchitis caused by a single organism (29 by Haemophilus influenzae, 27 by Branhamella catarrhalis, 9 by gram-negative enteric organisms, 6 by Streptococcus pneumoniae), while more than one pathogen was implicated in 15 patients (18%). A total of 70.8% of the cefixime group and 50% of the cephalexin group were clinically cured (chi 2 = 3.89, P less than 0.05); however, when the categories of cured and improved were combined, no significant difference was noted between treatment groups (chi 2 = 3.39, P = 0.06). Analysis of side effects included all 130 evaluable and nonevaluable patients: diarrhea was noted in six patients in the cefixime group and none of the patients in the cephalexin group (P = 0.013 by the Fisher exact test). The diarrhea was mild and self-limited in all cases. B. catarrhalis has emerged as a major cause of exacerbation of bronchitis in our experience; there is an increased need to emphasize the examination of sputum samples by Gram staining if cost-effective antibiotic choices are to be made; any empirically chosen antibiotic should have activity against beta-lactamase-producing strains of B. catarrhalis as well as S. pneumoniae and H. influenzae.

Full text

PDF
1041

Images in this article

1042Image
on p.1042
1043Image
on p.1043

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez S., Jones M., Holtsclaw-Berk S., Guarderas J., Berk S. L. In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 1985 Apr;27(4):646–647. doi: 10.1128/aac.27.4.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anthonisen N. R., Manfreda J., Warren C. P., Hershfield E. S., Harding G. K., Nelson N. A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Jones R. N. Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates. Pediatr Infect Dis J. 1987 Oct;6(10):954–957. [PubMed] [Google Scholar]
  4. Chodosh S. Acute bacterial exacerbations in bronchitis and asthma. Am J Med. 1987 Apr 27;82(4A):154–163. [PubMed] [Google Scholar]
  5. ELMES P. C., FLETCHER C. M., DUTTON A. A. Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. Br Med J. 1957 Nov 30;2(5056):1272–1275. doi: 10.1136/bmj.2.5056.1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Elmes P. C., King T. K., Langlands J. H., Mackay J. A., Wallace W. F., Wade O. L., Wilson T. S. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J. 1965 Oct 16;2(5467):904–908. doi: 10.1136/bmj.2.5467.904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Faulkner R. D., Yacobi A., Barone J. S., Kaplan S. A., Silber B. M. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J. 1987 Oct;6(10):963–970. doi: 10.1097/00006454-198710000-00035. [DOI] [PubMed] [Google Scholar]
  8. Hager H., Verghese A., Alvarez S., Berk S. L. Branhamella catarrhalis respiratory infections. Rev Infect Dis. 1987 Nov-Dec;9(6):1140–1149. doi: 10.1093/clinids/9.6.1140. [DOI] [PubMed] [Google Scholar]
  9. Levison M. E., Johnson W. D., Thornhill T. S., Kaye D. Clinical and in vitro evaluation of cephalexin. A new orally administered cephalosporin antibiotic. JAMA. 1969 Sep 1;209(9):1331–1336. [PubMed] [Google Scholar]
  10. Nicotra B., Rivera M., Luman J. I., Wallace R. J., Jr Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease. Arch Intern Med. 1986 May;146(5):890–893. [PubMed] [Google Scholar]
  11. Nicotra M. B., Rivera M., Awe R. J. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med. 1982 Jul;97(1):18–21. doi: 10.7326/0003-4819-97-1-18. [DOI] [PubMed] [Google Scholar]
  12. Pfeffer M., Jackson A., Ximenes J., de Menezes J. P. Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine. Antimicrob Agents Chemother. 1977 Feb;11(2):331–338. doi: 10.1128/aac.11.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pines A., Raafat H., Greenfield J. S., Linsell W. D., Solari M. E. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest. 1972 Apr;66(2):107–115. [PubMed] [Google Scholar]
  14. Pollard J. A., Wallace R. J., Jr, Nash D. R., Luman J. I., Wilson R. W. Incidence of Branhamella catarrhalis in the sputa of patients with chronic lung disease. Drugs. 1986;31 (Suppl 3):103–108. doi: 10.2165/00003495-198600313-00022. [DOI] [PubMed] [Google Scholar]
  15. Sarubbi F. A., Verghese A., Caggiano C., Holtsclaw-Berk S., Berk S. L. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 1989 Jan;33(1):113–114. doi: 10.1128/aac.33.1.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schleupner C. J., Anthony W. C., Tan J., File T. M., Lifland P., Craig W., Vogelman B. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch Intern Med. 1988 Feb;148(2):343–348. [PubMed] [Google Scholar]
  17. Sweeney K. G., Verghese A., Needham C. A. In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains. Antimicrob Agents Chemother. 1985 Apr;27(4):499–502. doi: 10.1128/aac.27.4.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tager I., Speizer F. E. Role of infection in chronic bronchitis. N Engl J Med. 1975 Mar 13;292(11):563–571. doi: 10.1056/NEJM197503132921105. [DOI] [PubMed] [Google Scholar]
  19. Tally F. P., Desjardins R. E., McCarthy E. F., Cartwright K. Safety profile of cefixime. Pediatr Infect Dis J. 1987 Oct;6(10):976–980. doi: 10.1097/00006454-198710000-00037. [DOI] [PubMed] [Google Scholar]
  20. Wallace R. J., Jr, Steingrube V. A., Nash D. R., Hollis D. G., Flanagan C., Brown B. A., Labidi A., Weaver R. E. BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob Agents Chemother. 1989 Nov;33(11):1845–1854. doi: 10.1128/aac.33.11.1845. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES